期刊论文

Application of new orally anticoagulants in patients with chronic kidney disease

中文

基础医学与临床

1001-6325

2020

40

8

1103-1108

10.16352/j.issn.1001-6325.2020.08.021

国家自然科学基金(81700306) 湖南省自然科学基金(2018JJ3469) 中国博士后科学基金(2017M622588) 湖南省卫生健康委(C2019115)。

本校为第一机构

新型口服抗凝剂(NOACs)是一种新研发的凝血因子抑制剂,在各种血栓事件及缺血性心血管事件中发挥着重要的作用,但其在慢性肾病(CKD)3~5期患者中的使用仍存在争议。对不同分期CKD患者推荐使用NOACs、监测评价NOACs所致抗凝相关肾病及NOACs临床应用。

Novel oral anticoagulants (NOVACs) as blood coagulation factor inhibitors have exhibited pivotal role in thromboembolic event and ischemic cardiovascular disease. Nevertheless, it's application in chronic kidney disease (CKD) patients of stage 3-5 remains controversial. This paper reviewed currently recommended usage of NOACs in CKD patients of stage 3-5 in the evaluation of anticoagulation related nephrop...